套细胞淋巴瘤治疗的转折点
Turning Point in the Treatment of Mantle Cell Lymphoma.
作者信息
Motokura Toru
机构信息
Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
出版信息
Yonago Acta Med. 2019 Mar 28;62(1):1-7. doi: 10.33160/yam.2019.03.001. eCollection 2019 Mar.
Mantle cell lymphoma (MCL) is an incurable type of B-cell lymphoma. It is typically composed of small-to-medium-sized cleaved lymphoid cells with cyclin D1 protein expression due to the chromosomal translocation t(11;14)(q13;q32). Even with the development of rituximab, an anti-CD20 antibody drug, the long-term outcome of patients with MCL has not improved. Recently, new agents have been used in clinical settings, and the outcome of patients with MCL is expected to improve. The treatment of MCL may be at a turning point from intensive chemotherapy to chemotherapy-free treatment. In this study, a recent progress in the diagnosis and treatment of MCL is reviewed.
套细胞淋巴瘤（MCL）是一种无法治愈的B细胞淋巴瘤。它通常由小到中等大小的核分裂淋巴样细胞组成，由于染色体易位t(11;14)(q13;q32)而表达细胞周期蛋白D1蛋白。即使有抗CD20抗体药物利妥昔单抗的出现，MCL患者的长期预后仍未得到改善。最近，新的药物已应用于临床，MCL患者的预后有望得到改善。MCL的治疗可能正处于从强化化疗转向无化疗治疗的转折点。在本研究中，对MCL诊断和治疗的最新进展进行了综述。
Zotero 插件